9 unknown, 5 completed, 1 active not recruiting, 1 recruiting. 17 Phase 2, 12 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Unknown 9, Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 12 | Unknown 9, Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Cyclophosphamide (CY): new trials by email Literature Review of Cyclophosphamide (CY) trials Research Report on Cyclophosphamide (CY)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF) - Immunodeficiency, Hematopoietic Stem Cell Transplantation | Phase 2 | Recruiting | National Cancer Institute (NCI) | 54 | 2023-02-23 | 2026-10-16 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU) - Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 232 | 2022-07-01 | 2022-07-08 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 242 | 2022-07-01 | 2023-03-21 |
| Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders Fludarabine, Dexamethasone, Cyclophosphamide - Stem Cell Transplantation | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-02 | 2023-09-21 | |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU) - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 242 | 2021-01-15 | 2021-01-19 |
| Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - TP53, Myeloid Tumors | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 196 | 2019-10-01 | 2019-10-10 |
| Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 196 | 2019-09-01 | 2019-09-23 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 22 | 2019-01-02 | 2026-01-06 |
| BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 20 | 2018-11-01 | 2018-11-07 |
| Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - Allogeneic Hematopoietic Stem Cell Transplantation, Conditions | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2018-07-01 | 2018-07-24 |
| Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Conditioning | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2018-01-02 | 2020-02-25 |
| BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2017-07-05 | 2017-10-12 |
| G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 202 | 2016-04-18 | 2022-02-14 |
| IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT Idarubicin（IDA）, Busulfan (BU), Cyclophosphamide (CY) - Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 153 | 2016-01-01 | 2020-03-03 |
| BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT Busulfan (BU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan | Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 550 | 2016-01-01 | 2022-04-08 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY) - Hematologic Malignancy, Leukemia | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 4 | 2012-03-01 | 2025-05-04 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Fludarabine, Busulfan, Total Body Irradiation (TBI) - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 40 | 2011-08-04 | 2026-04-15 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY) - Hematologic Malignancies | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 27 | 2006-01-01 | 2025-05-04 |
Leukemia, Myeloid, Acute (4) · Myelodysplastic Syndromes (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Hodgkin Disease (3) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Anemia, Aplastic (1) · Anemia, Refractory (1) · Anemia, Refractory, with Excess of Blasts (1) · Autoimmune Diseases (1) · Burkitt Lymphoma (1) · Congenital Abnormalities (1)
Nanfang Hospital, Southern Medical University (12) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3) · M.D. Anderson Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · National Cancer Institute (NCI) (1)
China (12) · United States (6)
Qifa Liu (10) · Neal Flomenberg, MD (2) · Bhavisha A Patel, M.D. (1) · Dolores Grosso, DNP, CRNP (1) · Jeremy Ramdial, Ramdial (1) · Usama Gergis, MD (1)
PMID 21868572, PMID 36084276, PMID 36251488, PMID 36588387, PMID 36702138, PMID 41175032